Catalent Completes $14M Biologics Packaging Expansion

Catalent has completion a $14 million expansion to increase its biologics packaging capabilities and capacity at its Bloomington, IN facility.
 
The expansion adds 15,000 square feet of packaging infrastructure to the biologics and sterile manufacturing site, including five new packaging suites and a new quality control laboratory.

Catalent has partnered with industry leaders to bring new technologies and integrated capabilities to its three new packaging lines, including an Optima combination syringe assembly machine, an automated Mikron auto-injector assembly machine, and a Dividella NeoTOP® x (NTX) top-load cartoner with both semi-automated and fully-automated configurations. All three high-speed lines are fully qualified and ready to provide more flexible packaging services for vials, syringes, and devices with no glass-to-glass contact.
 
"The completion of this expansion marks a major milestone for our late-stage and commercial customers, allowing Catalent to focus on more complex device assembly and packaging needs for biologic products at higher volumes," commented Mike Riley, Region President, Biologics North America. "This state-of-the-art equipment adds to our growing network of global packaging capabilities alongside our Brussels, Belgium, and Anagni, Italy drug product manufacturing sites."
 
Catalent’s 875,000 square-feet facility in Bloomington has expertise in sterile formulation and biomanufacturing and drug product fill/finish capacity across liquid and lyophilized vials, prefilled syringes, and cartridges.
 

CPhI China 2020 To Be Postponed to Dec. 16-18th,

Register as Visitor to the 20th Edition of CPhI China!

-----------------------------------------------------------------------
Editor's Note:

En-CPhI.CN is a vertical B2B online trade platform serving the pharmaceutical industry,

for any copyright disputes involved in the articles,

please email: Julia.Zhang@imsinoexpo.com to motify or remove the content.